From the Interventional Neuroradiology Unit (F.C., N.L., S.N., L.R., A.R., A.L., S.M.), Careggi University Hospital, Florence, Italy
From the Interventional Neuroradiology Unit (F.C., N.L., S.N., L.R., A.R., A.L., S.M.), Careggi University Hospital, Florence, Italy.
AJNR Am J Neuroradiol. 2019 Mar;40(3):497-502. doi: 10.3174/ajnr.A5967. Epub 2019 Feb 14.
Flow diversion for anterior communicating artery aneurysms required further investigation.
Our aim was to analyze outcomes after treatment of anterior communicating artery aneurysms with flow-diverter stents.
A systematic search of 3 data bases was performed for studies published from 2008 to 2018.
According to the Preferred Reporting Items for Systematic Reviews and Meta-Analyses guidelines, we included studies reporting anterior communicating artery aneurysms treated with flow diversion.
Random-effects meta-analysis was used to pool the following: aneurysm occlusion rate, complications, and factors influencing the studied outcomes.
We included 14 studies and 148 unruptured saccular anterior communicating artery aneurysms treated with flow diversion. The long-term complete/near-complete (O'Kelly-Marotta C-D) occlusion rate was 87.4% (91/105; 95% CI, 81.3%-93.6%; I = 0%) (mean radiologic follow-up of 11 months). The treatment-related complication rate was 8.6% (14/126; 95% CI, 4%-13.1%; I = 0%), with morbidity and mortality rates of 3.5% (5/126; 95% CI, 2%-7%; I = 0%) and 2.5% (2/148; 95% CI, 0.3%-5%; I = 0%), respectively. Most complications were periprocedural (12/126 = 7%; 95% CI, 3%-11%; I = 0%). Thromboembolic events were slightly higher compared with hemorrhagic complications (10/126 = 6%; 95% CI, 2%-10%; I = 0% and 4/126 = 3%; 95% CI, 1%-6%; I = 0%). Branching arteries (A2 or the recurrent artery of Heubner) covered by the stent were occluded in 16% (7/34; 95% CI, 3.5%-28%; I = 25%) of cases. Pre- and posttreatment low-dose and high-dose of antiplatelet therapy was not associated with significantly different complication and occlusion rates.
We reviewed small and retrospective series.
Flow diversion for unruptured saccular anterior communicating artery aneurysms appears to be an effective alternative treatment for lesions difficult to treat with coiling or microsurgical clipping. The treatment-related complication rate was relatively low. However, larger studies are needed to confirm these results.
前交通动脉瘤的血流导向治疗需要进一步研究。
本研究旨在分析血流导向支架治疗前交通动脉瘤的结果。
对 2008 年至 2018 年发表的研究进行了 3 个数据库的系统检索。
根据系统评价和荟萃分析的首选报告项目,我们纳入了报道使用血流导向装置治疗前交通动脉瘤的研究。
使用随机效应荟萃分析汇总以下内容:动脉瘤闭塞率、并发症以及影响研究结果的因素。
共纳入 14 项研究和 148 例未破裂的囊状前交通动脉瘤,接受血流导向治疗。长期完全/近完全闭塞(O'Kelly-Marotta C-D)率为 87.4%(91/105;95%CI,81.3%-93.6%;I=0%)(平均影像学随访 11 个月)。治疗相关并发症发生率为 8.6%(14/126;95%CI,4%-13.1%;I=0%),发病率和死亡率分别为 3.5%(5/126;95%CI,2%-7%;I=0%)和 2.5%(2/148;95%CI,0.3%-5%;I=0%)。大多数并发症为围手术期并发症(12/126=7%;95%CI,3%-11%;I=0%)。与出血性并发症相比,血栓栓塞事件略高(10/126=6%;95%CI,2%-10%;I=0%和 4/126=3%;95%CI,1%-6%;I=0%)。支架覆盖的分支动脉(A2 或 Heubner 返动脉)闭塞率为 16%(7/34;95%CI,3.5%-28%;I=25%)。术前和术后低剂量和高剂量抗血小板治疗与并发症和闭塞率无显著相关性。
我们回顾了小型和回顾性系列研究。
对于用线圈栓塞或显微手术夹闭难以治疗的病变,血流导向装置治疗未破裂的囊状前交通动脉瘤似乎是一种有效的替代治疗方法。治疗相关并发症发生率相对较低。然而,需要更大的研究来证实这些结果。